Company Filing History:
Years Active: 2019-2022
Title: Paul Secrist: Innovator in Cancer Treatment
Introduction
Paul Secrist is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. With a total of 2 patents to his name, Secrist's work is recognized for its potential impact on medical science.
Latest Patents
Secrist's latest patents focus on MCL-1 inhibitors and methods of use thereof. One of the disclosed compounds is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and its enantiomers and pharmaceutically acceptable salts. The patents also describe pharmaceutical compositions of this compound and methods for treating cancer using these innovative formulations.
Career Highlights
Paul Secrist is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on groundbreaking research and development in cancer therapies.
Collaborations
Secrist has collaborated with notable colleagues, including Alexander Hird and Matthew Belmonte. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Paul Secrist is a prominent inventor whose work in cancer treatment through MCL-1 inhibitors showcases his dedication to improving medical outcomes. His contributions to the field are significant and continue to influence pharmaceutical innovations.